{"entity":{"id":"nct07287995","kind":"trial","name":"A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors","aka":[],"tldr":"An early study of ASP2998, an experimental antibody drug carrying a cancer-killing payload and an immune activator. It is recruiting people with advanced solid tumors for treatment alone or with tumor-specific standard therapies.","summary":"NCT07287995 evaluates the TROP2-directed dual-payload ADC ASP2998 alone and in tumor-specific combinations with pembrolizumab, enfortumab vedotin or carboplatin. ASP2998 carries a TOP1 inhibitor and a STING agonist. The registry last posted 2 September 2026 lists recruiting status, actual start on 5 February 2026, estimated enrollment of 428 and estimated primary completion on 30 June 2029. The earlier ASCO 2026 trial-in-progress abstract planned 196 participants; neither figure is a treated-patient count. No results are posted. The trial includes urothelial, non-small-cell lung, gastric/gastroesophageal junction and HER2-negative breast cancer cohorts. Prior TROP2, STING or TOP1 therapy permissions differ by cohort; the current protocol, rather than the older trial-in-progress abstract, determines eligibility. This is advanced disease research, not established adjuvant treatment.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07287995","url":"https://clinicaltrials.gov/study/NCT07287995"},{"label":"Astellas study 2998-CL-0101","url":"https://www.clinicaltrials.astellas.com/study/2998-CL-0101"},{"label":"Astellas: TOP1 inhibitor and STING agonist payloads","url":"https://www.astellas.com/content/dam/astellas-com/global/en/confidential-documents/financial-results/4q2025_pre_en.pdf"},{"label":"ASCO 2026 trial-in-progress abstract TPS2665","url":"https://doi.org/10.1200/jco.2026.44.16_suppl.tps2665"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc","dual-payload-adc"],"targets":["trop2"],"drugs":["asp2998","pembrolizumab","enfortumab-vedotin","carboplatin"],"companies":["astellas"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07287995","phase":"1/2","setting":"A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"Astellas Pharma Global Development, Inc.","participation":[{"nct":"NCT07287995","source":"https://clinicaltrials.gov/study/NCT07287995","fetchedAt":"2026-10-07T16:55:38.126Z","studySha256":"94b8bc898a51f21d4edf6c7f72b96f323949078eb985ecd860cad0609c7e947c","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-02","leadSponsor":"Astellas Pharma Global Development, Inc.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":428,"enrolmentType":"ESTIMATED","siteCount":8,"recruitingSiteCount":8,"countries":["Japan","United States"]}],"started":"2026-02-05","startedType":"actual","enrolled":428,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07287995/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"dual-payload-adc","kind":"technology","name":"Dual-payload ADC","route":"/technologies/dual-payload-adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"asp2998","kind":"drug","name":"ASP2998","route":"/drugs/asp2998/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"enfortumab-vedotin","kind":"drug","name":"Enfortumab vedotin","route":"/drugs/enfortumab-vedotin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"astellas","kind":"company","name":"Astellas","route":"/companies/astellas/"}]}}